S-1/A: CTT Pharma Files for Resale of Shares via Equity Line

CTT Pharmaceutical Holdings, Inc. has filed an amended S-1 registration statement to allow for the resale of up to 6,250,000 shares of common stock by RH2 Equity Partners, issued under an Equity Line of Credit.

Summary

• CTT Pharmaceutical Holdings, Inc. is filing an amended registration statement (Form S-1/A) to permit RH2 Equity Partners (the Selling Stockholder) to resell up to 6,250,000 shares of common stock.
• These shares were issued or may be issued to RH2 Equity Partners under an Equity Line of Credit (ELOC) agreement dated September 19, 2025.
• The company is not selling any securities in this offering and will not receive proceeds from the Selling Stockholder's resale of these shares.
• CTT Pharma may receive up to $10 million in gross proceeds from future sales of its common stock to the Selling Stockholder under the ELOC, which it intends to use for working capital, strategic initiatives, and general corporate purposes, with a priority of at least $500,000 for in-house manufacturing equipment.
• The company aims to limit the use of the ELOC to minimize dilution, particularly at current low stock prices, and plans to raise additional funds only if the stock price exceeds $1.00.
• The company is a development-stage entity focused on fast-dissolving drug delivery systems, specifically oral dissolvable thin strips, with current efforts focused on nicotine and vitamin strips.
• The company has a history of losses and its auditors have issued a going concern qualification.
• The company's common stock is listed on the OTCQB under the symbol CTTH, with a last reported closing price of $0.08 on June 26, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's development-stage status, history of losses, going concern qualification, and the dilutive nature of its primary financing mechanism (ELOC).

Positives

• Secured an Equity Line of Credit (ELOC) of up to $10 million with RH2 Equity Partners to provide potential future funding.
• Development of patented fast-dissolving oral strip technology with applications in pharmaceuticals, nutraceuticals, and nicotine.
• Focus on nicotine and vitamin strips as initial commercialization targets, with vitamin strips not requiring FDA approval for quicker market entry.
• Received a Continuation-In-Part (CIP) patent approval in the US for nicotine strips, strengthening patent protection.
• In preliminary discussions with a European company for a potential partnership.
• Management is actively seeking to add an independent director to comply with OTCQB standards.
• The company has a founder with extensive patent history and experience in drug delivery systems.

Negatives

• The company is in a development stage and has a history of losses, with auditors issuing a going concern qualification.
• The company has limited operating history and has not generated significant revenue.
• The ELOC agreement involves selling shares at 85% of the VWAP, which can lead to significant dilution, especially at current low stock prices.
• The company's common stock is a 'penny stock' subject to additional regulatory restrictions.
• The company has identified material weaknesses in its internal controls over financial reporting, including a lack of written documentation and insufficient segregation of duties.
• The company has not yet finalized its regulatory, commercialization, or partnership strategy for international markets.
• The company has no active manufacturing agreement in place and intends to use offering proceeds to acquire its own equipment.
• The company does not anticipate paying cash dividends in the foreseeable future.

Risks

• The company is in a development stage and may never achieve operational success.
• The ELOC may result in significant dilution of existing shareholders, with up to 166 million shares potentially issued to raise $10 million at current stock prices.
• The company has a history of losses and its auditors have included a going concern qualification.
• The company has generated limited operating revenue and is not expecting significant revenues in the short-term.
• The company will be subject to extensive governmental regulation, which increases costs and may affect its ability to produce strips.
• Delays in obtaining governmental regulatory approval could adversely affect marketing and revenue generation.
• The company may incur substantial product liability expenses.
• The company may fail or be delayed in commercializing its strip technology.
• The company may be unable to adequately protect its patent and proprietary rights.
• The company faces rapid technological change and intense competition from larger, more resourced companies.
• The company may not be able to adequately manage its growth.
• The loss of executive officers or key employees could have a material adverse effect.
• The company has only one independent director and is working to appoint a second.
• Management controls a significant percentage of outstanding stock, potentially influencing corporate actions.
• Intellectual property infringement claims could be expensive and unsuccessful.
• The company may incur significant increased costs as a result of operating as a public company.
• The company's proposed business expansion for nicotine strips in the United States is dependent on FDA Approval, which can take 1-1.5 years.
• There is a limited market for the company's common stock, and its price may be volatile.
• Offers or availability for sale of a substantial number of shares could cause the price of common stock to decline.
• The company is subject to penny stock regulations and restrictions, which may make it difficult to sell shares.
• The company may choose to or be compelled to undertake product recalls.
• The company's products and systems may be subject to security incidents or data breaches.
• The company is an emerging growth company and a smaller reporting company, availing itself of reduced disclosure requirements which could make its stock less attractive.
• The company is required to evaluate the effectiveness of its internal control over financial reporting.
• The actual number of shares sold under the ELOC and the gross proceeds are uncertain.
• Investors may experience a decline in the value of shares purchased due to future sales at lower prices.
• The company may require additional financing to sustain operations.
• Management will have broad discretion over the use of proceeds from the offering.

Future Outlook

The company intends to use proceeds from the ELOC for working capital, strategic initiatives, and general corporate purposes, with a priority for acquiring in-house manufacturing equipment. They plan to focus on nicotine and vitamin strips for initial commercialization, with nicotine strips requiring FDA approval and vitamin strips aiming for a quicker market entry. Pharmaceutical products are likely to be pursued through partnerships due to higher development costs. The company anticipates continued operating losses in the near term.

Management Comments

• The current CEO, who owns over 10% of our shares has been mindful of not diluting shareholders and will continue to make decisions that are in the best interests of shareholders.
• Management believes that if our stock price substantially increases that we will be required to sell substantially fewer shares under the ELOC to reach our goals and that this will reduce dilution to our shareholder, but no assurance can be given that this will occur.
• We would look to raise additional funding if the stock goes over $1.00 a share.
• Our priority is to spend at least $500,000 on equipment to bring our manufacturing in house.
• We have also determined to limit our use of the ELOC to minimize the dilution that might occur, especially at our current stock price levels.
• The CEO of CTT has a identified a real need for our technology in the tobacco/nicotine industry as more than 480,000 American die each year from the effects of smoking or 1300 per day and more than 8 million deaths worldwide.
• The $10 Million Equity Line of Credit that CTT has signed with RH2 Equity Partners will give the company the ability to independently launch this much needed product as well as our vitamin strips.
• Management believes that the proceeds of this offering will allow the Company top acquire its own machinery to produce its strips and result in substantial benefit to our shareholders.
• Management believes that our orally dissolving strips could be an excellent fast dissolving drug delivery system which can be used by veterinarians to treat dogs, cats and other animals who would ordinarily be given a pill or injection.

Industry Context

StockSavvy.ai notes that CTT Pharmaceutical Holdings is operating in the highly competitive drug delivery and pharmaceutical sectors. The company's focus on oral dissolvable strips for nicotine and vitamin products positions it within growing markets for smoking cessation alternatives and health supplements. However, the path to market, particularly for nicotine products requiring FDA approval, is complex and capital-intensive, facing competition from established players and alternative delivery methods. The company's strategy to leverage its patented technology for both regulated (nicotine) and less regulated (vitamins) products reflects a common approach to navigate market entry challenges.

Comparison to Industry Standards

• The company's focus on oral dissolvable strips aligns with broader industry trends in drug delivery seeking improved patient compliance, faster onset of action, and alternative administration routes to injections or traditional pills.
• The nicotine strip product aims to address the significant public health issue of smoking cessation, a market with established Nicotine Replacement Therapies (NRTs) like patches, gums, and lozenges, where CTT aims to offer a competitive alternative.
• The vitamin strip product enters the large and growing nutraceutical market, where innovation in delivery systems can offer differentiation.
• The company's reliance on patents for its technology is standard practice in the pharmaceutical and biotech industries to secure competitive advantage and market exclusivity.
• The company's development stage and need for significant capital align with typical trajectories of early-stage biotech and pharmaceutical companies, often requiring substantial funding rounds or strategic partnerships to advance products through regulatory and commercialization phases.

Corporate Governance

Legal Proceedings

• The company is not currently party to any legal proceedings.

Related Party Transactions

• The company has not engaged in any related party transactions in the last three years.

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the ELOC, but also potential for future gains if the company's technology is successfully commercialized. Management's control over a significant percentage of stock could influence decisions.
• Employees: The company has a small team and relies on independent contractors. Future hiring and compensation will depend on funding availability.
• Creditors: The company has a history of losses and a going concern qualification, which could impact its ability to meet obligations.
• Suppliers: The company sources raw materials from third-party suppliers and intends to bring manufacturing in-house, which could alter supplier relationships.
• Customers: The company aims to provide alternative products for smoking cessation and health supplements, potentially impacting consumer choices in these markets.

Next Steps

• The company intends to use proceeds from the ELOC for working capital, strategic initiatives, and general corporate purposes, including acquiring manufacturing equipment.
• The company plans to pursue FDA approval for its nicotine dissolvable strips and aims to bring vitamin strips to market in 2026.
• The company will continue to seek additional funding if needed.
• The company is evaluating commercialization pathways for its nicotine oral dissolvable strip technology, including direct commercialization and strategic partnerships.
• The company aims to bring vitamin strips to market in the United States in 2026.
• The company will look to partner with other pharmaceutical companies for pharmaceutical drug development and manufacturing.
• The company will look to solicit companies in multiple countries for exclusive distribution rights for its patented strips.
• The company will continue to seek to elect a second independent director to comply with OTCQB standards.

Key Dates

Recommendation

The company is in a high-risk, development-stage phase with a clear path to potential revenue through its patented strip technology, particularly in the nicotine and vitamin markets. However, significant risks remain, including substantial dilution from its primary financing mechanism (ELOC), a going concern qualification, and the lengthy regulatory process for nicotine products. While the technology shows promise and the company is actively pursuing commercialization and partnerships, the uncertainties warrant a 'hold' recommendation until further progress is demonstrated in revenue generation, regulatory approvals, and successful capital management that mitigates dilution.

Keywords

CTT Pharmaceutical Holdings, S-1/A Filing, Equity Line of Credit, RH2 Equity Partners, Common Stock Resale, Drug Delivery Systems, Oral Dissolvable Strips, Nicotine Strips, Vitamin Strips, FDA Approval, Development Stage Company, Going Concern, Dilution, OTCQB, CTTH